Gilead Sciences (GILD) Equity Ratio (2009 - 2026)

Gilead Sciences has reported Equity Ratio for 18 years, with the latest figure at 0.42 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 23.6% year-over-year to 0.42; the trailing twelve-month figure through Mar 2026 stood at 0.42 (up 23.6% YoY), and the FY2025 full-year result was 0.38, up 17.91% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.42, up from 0.38 in the prior quarter.
• The five-year high for Equity Ratio was 0.42 in Q1 2026, with the low at 0.31 in Q1 2024.
• Historically, Equity Ratio has averaged 0.35 across 5 years, with a median of 0.34 in 2023.
• Annual changes were most pronounced in 2024 — Equity Ratio dropped 10.91% — and 2026, when it increased 23.6%.
• Gilead Sciences' Equity Ratio stood at 0.34 in 2022, then climbed by 9.07% to 0.37 in 2023, then declined by 10.91% to 0.33 in 2024, then gained by 17.91% to 0.38 in 2025, then gained by 8.63% to 0.42 in 2026.
• The last three Equity Ratio figures came in at 0.42 (Q1 2026), 0.38 (Q4 2025), and 0.37 (Q3 2025), per Business Quant data.